PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
8.56%
Revenue growth under 50% of AVGO's 25.30%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
5.96%
Gross profit growth under 50% of AVGO's 100.51%. Michael Burry would be concerned about a severe competitive disadvantage.
15.72%
EBIT growth below 50% of AVGO's 285.80%. Michael Burry would suspect deeper competitive or cost structure issues.
15.72%
Operating income growth under 50% of AVGO's 285.80%. Michael Burry would be concerned about deeper cost or sales issues.
23.74%
Net income growth under 50% of AVGO's 182.32%. Michael Burry would suspect the firm is falling well behind a key competitor.
30.00%
EPS growth under 50% of AVGO's 180.79%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
26.00%
Diluted EPS growth under 50% of AVGO's 176.80%. Michael Burry would worry about an eroding competitive position or excessive dilution.
-2.13%
Share reduction while AVGO is at 1.60%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-1.94%
Reduced diluted shares while AVGO is at 7.94%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
13.79%
Dividend growth 1.25-1.5x AVGO's 9.21%. Bruce Berkowitz would see if management’s capital return strategy is more aggressive yet sustainable.
146.87%
OCF growth above 1.5x AVGO's 21.34%. David Dodd would confirm a clear edge in underlying cash generation.
169.29%
Positive FCF growth while AVGO is negative. John Neff would see a strong competitive edge in net cash generation.
106.56%
10Y revenue/share CAGR at 50-75% of AVGO's 199.69%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
124.91%
5Y revenue/share CAGR at 50-75% of AVGO's 245.17%. Martin Whitman would worry about a lagging mid-term growth trajectory.
32.49%
3Y revenue/share CAGR under 50% of AVGO's 146.17%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
36087.01%
10Y OCF/share CAGR above 1.5x AVGO's 181.58%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
2009.64%
5Y OCF/share CAGR above 1.5x AVGO's 669.57%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
-5.39%
Negative 3Y OCF/share CAGR while AVGO stands at 88.46%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
418.14%
Net income/share CAGR at 75-90% of AVGO's 531.89%. Bill Ackman would press for strategic moves to boost long-term earnings.
194.09%
Below 50% of AVGO's 697.30%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-12.16%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
261.31%
10Y equity/share CAGR in line with AVGO's 250.29%. Walter Schloss might see both benefiting from stable profitability and moderate payout ratios over the decade.
76.00%
Below 50% of AVGO's 189.73%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
43.76%
3Y equity/share CAGR at 75-90% of AVGO's 55.94%. Bill Ackman pushes for margin or operational changes to match the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.75%
Firm’s AR is declining while AVGO shows 32.54%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
1.96%
Inventory shrinking or stable vs. AVGO's 7.68%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
26.96%
Asset growth above 1.5x AVGO's 1.83%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
5.39%
BV/share growth above 1.5x AVGO's 3.03%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
7974.49%
We have some new debt while AVGO reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
-1.07%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
12.16%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.